In a recent report in Nature Communications, Kitai et al. designed a combinational treatment based on targeting the active-state KRASG12C-mutant variant that characterizes a substantial subset of non-small-cell lung cancer (NSCLC) cases. The authors highlighted that dual targeting with KRASG12C (ON) and mammalian target of rapamycin (mTOR) complex (mTORC)-1-selective inhibition potentially provides a new strategy to overcome drug resistance.
Keywords: ERK; KRAS(G12C); mTORC1; non-small-cell lung cancer.
Copyright © 2025 Elsevier Ltd. All rights reserved.